These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

762 related items for PubMed ID: 18847395

  • 1. Establishing the role of tigecycline in an era of antimicrobial resistance.
    Schafer JJ, Goff DA.
    Expert Rev Anti Infect Ther; 2008 Oct; 6(5):557-67. PubMed ID: 18847395
    [Abstract] [Full Text] [Related]

  • 2. Tigecycline: a novel glycylcycline antibiotic.
    Zhanel GG, Karlowsky JA, Rubinstein E, Hoban DJ.
    Expert Rev Anti Infect Ther; 2006 Feb; 4(1):9-25. PubMed ID: 16441206
    [Abstract] [Full Text] [Related]

  • 3. Tigecycline: an investigational glycylcycline antimicrobial with activity against resistant gram-positive organisms.
    Garrison MW, Neumiller JJ, Setter SM.
    Clin Ther; 2005 Jan; 27(1):12-22. PubMed ID: 15763603
    [Abstract] [Full Text] [Related]

  • 4. Tigecycline: first of a new class of antimicrobial agents.
    Rose WE, Rybak MJ.
    Pharmacotherapy; 2006 Aug; 26(8):1099-110. PubMed ID: 16863487
    [Abstract] [Full Text] [Related]

  • 5. Tigecycline: clinical evidence and formulary positioning.
    Nathwani D.
    Int J Antimicrob Agents; 2005 Mar; 25(3):185-92. PubMed ID: 15737510
    [Abstract] [Full Text] [Related]

  • 6. Potency and spectrum of tigecycline tested against an international collection of bacterial pathogens associated with skin and soft tissue infections (2000-2004).
    Fritsche TR, Sader HS, Stilwell MG, Dowzicky MJ, Jones RN.
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):195-201. PubMed ID: 16105564
    [Abstract] [Full Text] [Related]

  • 7. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections.
    Bradford PA, Weaver-Sands DT, Petersen PJ.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S315-32. PubMed ID: 16080070
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic applications of tigecycline in the management of complicated skin and skin structure infections.
    Grolman DC.
    Int J Infect Dis; 2007 May 01; 11 Suppl 1():S7-15. PubMed ID: 17603950
    [Abstract] [Full Text] [Related]

  • 9. Use of in vitro susceptibility and pathogen prevalence data to model the expected clinical success rates of tigecycline and other commonly used antimicrobials for empirical treatment of complicated skin and skin-structure infections.
    Sader HS, Mallick R, Kuznik A, Fritsche TR, Jones RN.
    Int J Antimicrob Agents; 2007 Dec 01; 30(6):514-20. PubMed ID: 17959359
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007).
    Nørskov-Lauritsen N, Marchandin H, Dowzicky MJ.
    Int J Antimicrob Agents; 2009 Aug 01; 34(2):121-30. PubMed ID: 19342205
    [Abstract] [Full Text] [Related]

  • 11. Tigecycline: the answer to beta-lactam and fluoroquinolone resistance?
    Fraise AP.
    J Infect; 2006 Nov 01; 53(5):293-300. PubMed ID: 16876253
    [Abstract] [Full Text] [Related]

  • 12. Tigecycline: a new glycylcycline for treatment of serious infections.
    Noskin GA.
    Clin Infect Dis; 2005 Sep 01; 41 Suppl 5():S303-14. PubMed ID: 16080069
    [Abstract] [Full Text] [Related]

  • 13. A Phase 3, open-label, non-comparative study of tigecycline in the treatment of patients with selected serious infections due to resistant Gram-negative organisms including Enterobacter species, Acinetobacter baumannii and Klebsiella pneumoniae.
    Vasilev K, Reshedko G, Orasan R, Sanchez M, Teras J, Babinchak T, Dukart G, Cooper A, Dartois N, Gandjini H, Orrico R, Ellis-Grosse E, 309 Study Group.
    J Antimicrob Chemother; 2008 Sep 01; 62 Suppl 1():i29-40. PubMed ID: 18684704
    [Abstract] [Full Text] [Related]

  • 14. A review of tigecycline--the first glycylcycline.
    Peterson LR.
    Int J Antimicrob Agents; 2008 Dec 01; 32 Suppl 4():S215-22. PubMed ID: 19134522
    [Abstract] [Full Text] [Related]

  • 15. In vitro activity of tigecycline against 6792 Gram-negative and Gram-positive clinical isolates from the global Tigecycline Evaluation and Surveillance Trial (TEST Program, 2004).
    Hoban DJ, Bouchillon SK, Johnson BM, Johnson JL, Dowzicky MJ, Tigecycline Evaluation and Surveillance Trial (TEST Program) Group.
    Diagn Microbiol Infect Dis; 2005 Jul 01; 52(3):215-27. PubMed ID: 16105567
    [Abstract] [Full Text] [Related]

  • 16. Antimicrobial activity of tigecycline against clinical isolates from Spanish medical centers. Second multicenter study.
    Betriu C, Rodríguez-Avial I, Gómez M, Culebras E, López F, Alvarez J, Picazo JJ, Spanish Tigecycline Group.
    Diagn Microbiol Infect Dis; 2006 Dec 01; 56(4):437-44. PubMed ID: 16949245
    [Abstract] [Full Text] [Related]

  • 17. In vitro evaluation of tigecycline and comparative agents in 3049 clinical isolates: 2001 to 2002.
    Bouchillon SK, Hoban DJ, Johnson BM, Stevens TM, Dowzicky MJ, Wu DH, Bradford PA.
    Diagn Microbiol Infect Dis; 2005 Apr 01; 51(4):291-5. PubMed ID: 15808321
    [Abstract] [Full Text] [Related]

  • 18. Tigecycline: an update.
    Stein GE, Babinchak T.
    Diagn Microbiol Infect Dis; 2013 Apr 01; 75(4):331-6. PubMed ID: 23357291
    [Abstract] [Full Text] [Related]

  • 19. In vitro activity of tigecycline (GAR-936) tested against 11,859 recent clinical isolates associated with community-acquired respiratory tract and gram-positive cutaneous infections.
    Fritsche TR, Kirby JT, Jones RN.
    Diagn Microbiol Infect Dis; 2004 Jul 01; 49(3):201-9. PubMed ID: 15246511
    [Abstract] [Full Text] [Related]

  • 20. Tigecycline: a glycylcycline antimicrobial agent.
    Doan TL, Fung HB, Mehta D, Riska PF.
    Clin Ther; 2006 Aug 01; 28(8):1079-1106. PubMed ID: 16982286
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.